Nebenwirkungen · Abiraterone Mylan
Abiraterone Mylan 500 mg film-coated tablets Abiraterone Mylan 1000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-146788 · Präparat HOS-099564
Table 1: Adverse reactions identified in clinical studies and post-marketing System Organ Class Adverse reaction and frequency Infections and infestations very common: urinary tract infection common: sepsis Immune system disorders not known: anaphylactic reactions Endocrine disorders uncommon: adrenal insufficiency Metabolism and nutrition disorders very common: hypokalaemia common: hypertriglyceridaemia Cardiac disorders common: cardiac failure*, angina pectoris, atrial fibrillation, tachycardia uncommon: other arrhythmias not known: myocardial infarction, QT prolongation (see sections 4.4 and 4.5) Vascular disorders very common: hypertension Respiratory, thoracic and mediastinal rare: allergic alveolitisa disorders Gastrointestinal disorders very common: diarrhoea common: dyspepsia Hepatobiliary disorders very common: alanine aminotransferase increased and/or aspartate aminotransferase increasedb rare: hepatitis fulminant, acute hepatic failure Skin and subcutaneous tissue disorders common: rash Musculoskeletal and connective tissue uncommon: myopathy, rhabdomyolysis disorders Renal and urinary disorders common: haematuria
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T13:57:00Z · SHA-256 a224b8fadc2ad3e1b1af874d8687b8e3d6bb14c5f714b2308f5ba81c1b78da11 · Passage db7c6648a33a8c8a553a4d10aec7b91e96ef134794bd4498db697573416bee38 · Zeichen 2304–4197 im Abschnitt